Cytokinetics (CYTK) Appoints Robert E. Landry to its Board

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of Robert E. Landry to its Board of Directors. Mr. Landry brings over three decades of financial and operational expertise in the pharmaceutical industry, most recently having served as the Chief Financial Officer at Regeneron Pharmaceuticals Inc. for 11 years.

“We are pleased to have Bob join our Board as we approach a key shareholder value inflection point for the company and prepare for the potential approval and launch of our first medicine,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “His extensive career in finance and expertise spanning financial engineering, capital allocation and efficiencies, tax strategy and treasury management will be important as we advance toward commercialization. His leadership at Regeneron, guiding the company’s global scaling, while maintaining disciplined spending and a steadfast commitment to innovation in research and development, aligns with our vision at Cytokinetics of becoming a fully integrated company achieving sustainable growth.”

In his role as Chief Financial Officer at Regeneron, Mr. Landry was responsible for all financial operations as well as investor relations, information technology, competitive intelligence and global non-manufacturing facilities, helping guide the company as it grew substantially in market capitalization and workforce over more than a decade. During his tenure he oversaw two public acquisitions, Checkmate Pharmaceuticals and Decibel Therapeutics, and established affiliates around the world.

Prior to joining Regeneron, Mr. Landry spent 25 years at Wyeth and Pfizer Inc., where he held numerous corporate and operational roles including Corporate Treasurer, Senior Vice President of Finance, Director of Pharmaceutical Marketing and Sales, and Chief Financial Officer of Wyeth Australia and New Zealand. Mr. Landry started his career at Coopers & Lybrand, now PricewaterhouseCoopers LLP. He was a Certified Public Accountant in New York and received a Bachelor of Business Administration from the University of Notre Dame.

You May Also Be Interested In

• DeFi Technologies posts $7.8M revenue and $2.3M loss in Q2 2026
• Versamet Royalties posts Q2 revenue of $23.7M, up 392% year over year
• L Catterton to sell $1B in Birkenstock shares in secondary offering